- Home
- ARGX vs KMI Comparison
ARGX vs KMI Comparison
Compare ARGX & KMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- KMI
- Stock Information
- Founded
- ARGX 2008
- KMI 1936
- Country
- ARGX Netherlands
- KMI United States
- Employees
- ARGX N/A
- KMI N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- KMI Natural Gas Distribution
- Sector
- ARGX Health Care
- KMI Utilities
- Exchange
- ARGX Nasdaq
- KMI Nasdaq
- Market Cap
- ARGX 51.1B
- KMI 58.3B
- IPO Year
- ARGX 2017
- KMI 2011
- Fundamental
- Price
- ARGX $917.87
- KMI $27.06
- Analyst Decision
- ARGX Strong Buy
- KMI Buy
- Analyst Count
- ARGX 17
- KMI 14
- Target Price
- ARGX $910.63
- KMI $31.43
- AVG Volume (30 Days)
- ARGX 367.0K
- KMI 15.1M
- Earning Date
- ARGX 10-30-2025
- KMI 10-22-2025
- Dividend Yield
- ARGX N/A
- KMI 4.34%
- EPS Growth
- ARGX N/A
- KMI 7.28
- EPS
- ARGX 23.27
- KMI 1.22
- Revenue
- ARGX $3,683,281,000.00
- KMI $16,416,000,000.00
- Revenue This Year
- ARGX $85.93
- KMI $12.32
- Revenue Next Year
- ARGX $35.17
- KMI $5.42
- P/E Ratio
- ARGX $36.91
- KMI $22.08
- Revenue Growth
- ARGX 92.98
- KMI 8.35
- 52 Week Low
- ARGX $510.06
- KMI $23.94
- 52 Week High
- ARGX $934.13
- KMI $31.48
- Technical
- Relative Strength Index (RSI)
- ARGX 70.28
- KMI 52.88
- Support Level
- ARGX $897.50
- KMI $26.32
- Resistance Level
- ARGX $932.29
- KMI $27.37
- Average True Range (ATR)
- ARGX 19.86
- KMI 0.52
- MACD
- ARGX -0.28
- KMI 0.04
- Stochastic Oscillator
- ARGX 82.07
- KMI 66.89
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
About KMI Kinder Morgan Inc.
Kinder Morgan operates natural gas, crude oil, and refined products pipelines connecting producing regions to demand centers. It is principally involved in the gathering, storage, and transmission of natural gas across the continental United States. It also operates distribution centers for refined products along with the largest fleet of Jones Act-compliant tankers.